BD hospital infection settlement
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson and French diagnostics firm BioMérieux settle an arbitration dispute initiated by BioMérieux in April to terminate an agreement granting detection method rights for methicillin resistant Staphylococcus aureus, a common hospital-acquired infection, to BD subsidiary GeneOhm Sciences, BD notes in an Aug. 8 Securities and Exchange Commission filing. BD/GeneOhm retains access to use the technology under the settlement (1"The Gray Sheet" April 30, 2007, p. 9)...
You may also be interested in...
Dispute Arises Over Hospital-Acquired Infection Tests
French diagnostic firm BioMérieux is attempting to renege on a licensing agreement with Becton Dickinson relating to methods for detecting one of the most common infections picked up in hospitals, according to BD
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.